Phase II Study of AB1010 in Patients With Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not Expressing FGFR3.

Trial Profile

Phase II Study of AB1010 in Patients With Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not Expressing FGFR3.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Aug 2013

At a glance

  • Drugs Masitinib (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 19 Oct 2011 Status changed from active, no longer recruiting to completed.
    • 17 Oct 2011 Results have been presented in an AB Science media release.
    • 27 Mar 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top